Premium
A comparative controlled trial of intralesionally‐administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis
Author(s) -
SHARQUIE K.E.,
NAJIM R.A.,
FARJOU I.B.
Publication year - 1997
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1997.tb01054.x
Subject(s) - medicine , sodium stibogluconate , cutaneous leishmaniasis , zinc , surgery , sodium , antimony , leishmaniasis , pathology , chemistry , organic chemistry , inorganic chemistry
Summary A comparative clinical trial between two newly introduced intralesional treatments for acute leishmaniasis and the established treatment of intralesionally‐administered pentavalent antimony compounds was performed. Treatments were allocated randomly to a total of 63 patients who received 2% zinc sulphate, 7% sodium chloride solutions or sodium stibogluconate intralesionally. A number of patients were left without treatment as controls. Patients were followed‐up for 45 days, the results showing that the three treatments gave comparable cure rates by the end of the follow‐up period. However, zinc sulphate gave a high cure rate (94.8%) usually with a single injection.